Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

G. Lopes; J. Segel; D. S. W. Tan; Y. Do; T. Mok; E. Finkelstein

doi:10.1200/jco.2011.29.15_suppl.7598

Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.7598 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 7598-7598 ◽

Cited By ~ 1

Author(s):

G. Lopes ◽

J. Segel ◽

D. S. W. Tan ◽

Y. Do ◽

T. Mok ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment ◽

Egfr Mutation Testing

Download Full-text

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

Value in Health ◽

10.1016/j.jval.2011.02.918 ◽

2011 ◽

Vol 14 (3) ◽

pp. A166

Author(s):

G. de Lima Lopes

Keyword(s):

Egfr Mutation ◽

Growth Factor Receptor ◽

Dominant Strategy ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment ◽

Egfr Mutation Testing

Download Full-text

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd010383.pub2 ◽

2016 ◽

Cited By ~ 40

Author(s):

Janette Greenhalgh ◽

Kerry Dwan ◽

Angela Boland ◽

Victoria Bates ◽

Fabio Vecchio ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Egfr Mutation ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd010383.pub3 ◽

2021 ◽

Author(s):

Janette Greenhalgh ◽

Angela Boland ◽

Victoria Bates ◽

Fabio Vecchio ◽

Yenal Dundar ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Egfr Mutation ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

10.1002/14651858.cd010383 ◽

2013 ◽

Cited By ~ 1

Author(s):

John A Green ◽

Victoria Bates ◽

Janette Greenhalgh ◽

Angela Boland ◽

Pooja Jain ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Egfr Mutation ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Pharmacoeconomic analysis of Giotrif® (afatinib) as first-line treatment of metastatic non-small cell lung cancer with Del19 mutation of epidermal growth factor receptor (EGFR) gene

Malignant tumours ◽

10.18027/2224-5057-2015-4-35-47 ◽

2015 ◽

pp. 35 ◽

Cited By ~ 1

Author(s):

Vera Andreevna Gorbunova ◽

Sergey Vladimirovich Orlov ◽

Sergey Kensarinovich Zyryanov ◽

Dmitriy Yuryevich Belousov

Keyword(s):

Lung Cancer ◽

Pharmacoeconomic Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Gene ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Overall survival (OS) of real-world patients with stage IIIb/IV non-small cell lung cancer (NSCLC) initiating epidermal growth factor receptor (EGFR) targeted tyrosine kinase inhibitors (TKI) as first-line treatment in England

Lung Cancer ◽

10.1016/s0169-5002(19)30138-2 ◽

2019 ◽

Vol 127 ◽

pp. S40

Author(s):

U. Rigney ◽

K. Lock ◽

C. Chen ◽

C. Escriu

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)

Translational Lung Cancer Research ◽

10.21037/tlcr.2019.11.19 ◽

2019 ◽

Vol 8 (6) ◽

pp. 1086-1090

Author(s):

Yusuke Chihara ◽

Tadaaki Yamada ◽

Junji Uchino ◽

Nobuyo Tamiya ◽

Yoshiko Kaneko ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 43

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 9

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7537 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7537-7537 ◽

Cited By ~ 7

Author(s):

T. Mok ◽

D. R. Spigel ◽

K. Park ◽

M. A. Socinski ◽

S. Y. Tung ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text